Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Regeneron Revives NGF Inhibitor With Phase II/III Data; Safety Issue Remains

Executive Summary

Regeneron Pharmaceuticals Inc. reported statistically significant pain relief for osteoarthritis sufferers enrolled in the company's Phase II/III clinical trial for fasinumab, but the data didn't relieve concerns about neuro-musculoskeletal side effects for medicines that inhibit nerve growth factor (NGF).


Related Content

Regeneron Partners NGF Antibody With Teva To Mitigate Risks
Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds
Creabilis Itching To Start Phase III Tests Of Lead Asset For Chronic Pruritus
Pfizer/Lilly ready to ditch painful past with new tanezumab trials
US FDA panel: Let anti-NGF studies move forward, despite 'severe' joint risks
J&J, Regeneron follow Pfizer in clinical holds for anti-NGFs
Pfizer forced to discontinue more trials for novel pain drug tanezumab
Pfizer suspends worldwide studies for tanezumab in osteoarthritis


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts